On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .
Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
A recent r and omized clinical trial showed buspirone efficacy in the treatment of attention-deficit/hyperactivity disorder ( ADHD ) in children . However , results from a recent multi-site controlled clinical trial of transdermal buspirone failed to separate it from placebo in a large sample of children with ADHD . Therefore , due to these inconsistent findings , this study was design ed to assess the efficacy of buspirone in the treatment of children with ADHD compared to methylpheni date in a double blind r and omized clinical trial . Forty out patients with a DSM-IV-TR diagnosis of ADHD were study population of this trial . Subjects were recruited from an outpatient child and adolescent clinic for a 6 week double blind , r and omized clinical trial . All study subjects were r and omly assigned to receive treatment using tablet of buspirone at a dose of 20 - 30 mg/day depending on weight ( 20 mg/day for < 30 kg and 30 mg/day for > 30 kg ) ( group 1 ) or methylpheni date at a dose of 20 - 30 mg/day depending on weight ( 20 mg/day for < 30 kg and 30 mg/day for > 30 kg ( group 2 ) for a 6 week double blind , r and omized clinical trial . The principal measure of outcome was the Teacher and Parent ADHD Rating Scale IV . Patients were assessed at baseline and at 21 and 42 days after the medication started . Significant differences were observed between the two groups on the Parent and Teacher Rating Scale scores . The changes at the endpoint compared to baseline were : -8.95±8.73 ( mean±SD ) and -15.60±7.81 ( mean±SD ) for buspirone and methypheni date , for Parent ADHD Rating Scale . The changes at the endpoint compared to baseline were : -9.80 ±7.06 ( mean±SD ) and -22.40±9.90 ( mean±SD ) for buspirone and methypheni date , respectively for Teacher ADHD Rating Scale . The difference between the buspirone and methylpheni date groups in the frequency of side effects was not significant except for decreased appetite , headache and insomnia that were observed more frequently in the methylpheni date group . The results of this study suggest that administration of buspirone was less effective than methylpheni date in the treatment of ADHD
On the CGI-I scale , the analysis revealed that MPH was more effective than ATX and GXR .
For any adverse events , RBX ( 89 % ) was the safest alternative .
Network meta- analysis offered a broader overview on the available treatments for ADHD , especially for safety issues , and contributes towards evidence gathering and clinical practice decisions .
The aim of this study is to gather evidence of head-to-head double-blind r and omized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder ( ADHD ) in children and adolescents .